{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wooding D"],"funding":["Wellcome Trust"],"pagination":["e0030424"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11580409"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(11)"],"pubmed_abstract":["Clinical trials of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using quantitative reverse-transcriptase PCR (RT-qPCR), which cannot differentiate replicant competent virus from non-viable virus or free RNA, limiting its utility as an endpoint. Culture-based methods for SARS-CoV-2 exist; however, these are often insensitive and poorly standardized for use as clinical trial endpoints. We report optimization of a culture-based approach evaluating three cell lines, three detection methods, and key culture parameters. We show that Vero-angiotensin-converting enzyme 2-transmembrane serine protease 2 cells in"],"journal":["mSphere"],"pubmed_title":["Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications."],"pmcid":["PMC11580409"],"funding_grant_id":["221590/Z/20/Z"],"pubmed_authors":["Wooding D","Davis K","Tate V","Nicholson B","Body R","Lendrem C","Logan M","Hayward G","CONDOR Steering Group","Edwards T","Watkins R","Fletcher T","Jones N","Jones W","Savage H","Lewington A","Allen AJ","Myerscough C","Atkinson B","Riley B","Bengey D","Buckle P","Lee J","Thompson CR","Micocci M","Cubas-Atienzar A","Lasserson D","Perera-Salazar R","Dark P","Simpson AJ","Wilcox M","Reynard C","Turner P","Buist K","Harden C","Greenhalf B","Halstead A","Price DA","Shaw V","Adams E","Byrne RL","Zhifang M","Kontogianni N","Inkson C","Prestwich G","Romero-Ramirez A","Khoo S","Greenland-Bews C","Gordon A","Gould S","Braybrook J"],"additional_accession":[]},"is_claimable":false,"name":"Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.","description":"Clinical trials of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using quantitative reverse-transcriptase PCR (RT-qPCR), which cannot differentiate replicant competent virus from non-viable virus or free RNA, limiting its utility as an endpoint. Culture-based methods for SARS-CoV-2 exist; however, these are often insensitive and poorly standardized for use as clinical trial endpoints. We report optimization of a culture-based approach evaluating three cell lines, three detection methods, and key culture parameters. We show that Vero-angiotensin-converting enzyme 2-transmembrane serine protease 2 cells in","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-04T13:40:19.429Z","creation":"2025-04-04T13:40:19.429Z"},"accession":"S-EPMC11580409","cross_references":{"pubmed":["39412283"],"doi":["10.1128/msphere.00304-24"]}}